Skip to content
Hair Pipeline
enfr
← Back to the pipeline

BL 3000

BL 3000 is in Phase 3 for telogen effluvium, developed by Biolab Sanus Farmacêutica.

An undisclosed Biolab oral capsule, registered for a Phase 3 in telogen effluvium against Pantogar that the registry never confirmed had started.

Phase 3OralUndisclosed

This programme is no longer being actively pursued.

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Biolab Sanus Farmacêutica
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Mechanism
Undisclosed

The sponsor has not said how it is supposed to work.

Indications
Telogen effluvium
Last public activity
July 2022
Copy last reviewed
September 2026
Record confidence
Low

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

Why it matters

Telogen effluvium, diffuse shedding after illness, childbirth or stress, is the complaint behind much of the hair-loss traffic on any site, and almost nothing prescription-grade is developed for it; the comparator here, Pantogar, is a registered medicine for diffuse hair loss in Brazil and Austria, and a non-inferiority study against it is how a new entrant would position itself. BL 3000 is a 500 mg capsule of undisclosed composition; the single-centre trial in 326 women was to start in January 2023 and the record, last updated in July 2022, still reads 'unknown'. Listed as inactive on the strength of the registry silence.

Development history

  1. Phase 3

    First Phase 3 trial on record: NCT04880889 — BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT04880889Phase 3Status unknown

    BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

    Biolab Sanus Farmaceutica · n=326 · January 2023

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same approach.

Cite this page

Hair Pipeline, "BL 3000 — development record", hairpipeline.com/pipeline/bl-3000